DNLIDenali Therapeutics Inc.

$3B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$331M+204.7% YoY

Gross Profit

$331M100.0% margin

Operating Income

-$197M-59.5% margin

Net Income

-$145M-43.9% margin

EPS (Diluted)

$-1.06

Cash Flow

Operating Cash Flow

-$358M

Free Cash Flow

-$371M

Stock-Based Comp.

$108M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$123M

Stockholders' Equity

$1.0B

Cash & Equivalents

$127M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$331M	$108M	+204.7%
Gross Profit	$331M	$108M	+204.7%
Operating Income	-$197M	-$341M	+42.3%
Net Income	-$145M	-$326M	+55.5%

DNLI FY 2023 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena